Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

About this update from Aurinia Pharmaceuticals Inc

ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS® (voclosporin) at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL , October 24–29, and the American Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston, TX , November 5–9. At ACR Convergence 2025, posters include: Title: Real-world Effectiveness and Usage of Voclosporin: Data from the ENLIGHT-LN Registry Presenting Author: Leanna Wise , M.D., Keck School of Medicine of USC Title: Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Sources Presenting Author: Eugenia Chock , M.D., M.P.H., Yale School of Medicine At ASN Kidney Week 2025, posters include: Title: Non-equilibrium Voclosporin Disposition Following IV and PO Administration : Tissue Levels in Kidney, Liver, Pancreas, and Heart Distinct from Plasma Drug Levels and Dependent on Route of Administration Presenter: Ernie Yap , M.D., Senior Medical Director at Aurinia Title: Voclosporin Distribution and Clearance from the Kidney and Cellular Location Following Co-administration with Ketoconazole and Rifampin Presenter: Ernie Yap , M.D., Senior Medical Director at Aurinia Title: Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the ENLIGHT-LN Registry Presenting Author: Mohammad Kamgar , M.D., David Geffen School of Medicine at UCLA “Alongside leading academic collaborators, we look forward to sharing new real-world and mechanistic data on voclosporin with the rheumatology and nephrology communities,” said Dr. Greg Keenan , Chief Medical Officer of Aurinia. “These findings reinforce our commitment to advancing care for patients living with lupus nephritis by deepening the medical community’s understanding of voclosporin’s role in real-world clinical practice and in combination with other therapies.” About Lupus Nephritis and LUPKYNIS Lupus nephritis (LN) is among the most severe and dangerous complications of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. LUPKYNIS is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active LN. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021 , the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. View source version on businesswire.com : https://www.businesswire.com/news/home/20251015580814/en/ General Inquiries [email protected] Source: Aurinia Pharmaceuticals Inc.

View stock analysis, news, and events for Aurinia Pharmaceuticals Inc